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fractional shortening (FS) two standard deviations below the
age adjusted mean (3) >10% decrease in EF or FS at day 100
from baseline.
Results: 92 of 100 consecutive patients completed day 100
screening (8 died). 25% (23 of 92) had LV dysfunction at day
100 (Table). 96%(22 of 23) were asymptomatic at time of
screening. Patients with LV dysfunction were older at the
time of SCT than those without (p¼0.068). Patients receiving
PBSC grafts had an increased incidence of LV dysfunction (p¼
0.032), likely related to the diagnosis of those patients (ma-
lignancy receiving autologous SCT and Fanconi Anemia).
Overall, however, diagnosis was not signiﬁcantly associated
with LV dysfunction. Patients with previous anthracycline
exposure had increased LV dysfunction compared to those
without (48% vs. 26%). GVHD, engraftment syndrome, and
viremias in the ﬁrst 100 days were not signiﬁcantly associ-
ated with decreased RV function. Death at 1 year was similar
in both groups.
Discussion: 25% of patients showed signs of cardiac
dysfunction at day 100, which was higher than anticipated.
Although there were no acute differences in outcome, the
long-term complications are unknown. Echocardiography at
day 100 identiﬁes SCT cardiac dysfunction, however, more
research is needed to understand the overall impact on long-
term outcome.288
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Background: Sleep disruption can adversely affect meta-
bolism, psychological well-being, performance, inﬂamma-
tory cytokines, immune function, and cardiac function and is
likely overlooked as a side effect of stem cell transplantation
(SCT). There are no objective studies evaluating sleep in pe-
diatric SCT patients. Actigraphic monitoring utilizes a small
monitor that is worn like a wristwatch and when used in
combination with self-reports of bedtime and rising time,
has been found to be a reliable and valid measure of sleep
patterns.
Purpose: To evaluate sleep patterns in SCT children and
young adults through actigraphy, sleep diaries, and evalua-
tion of environmental factors that inﬂuence sleep disruption.
Methods: Objective sleep parameters were measured with
the Micro-Motionlogger SleepWatch (Ambulatory Moni-
toring, Inc.) actigraph which was worn continuously. Sleep-
wake patterns were reported in a sleep diary to allow for
screening of artifacts (e.g., actigraph removal). The number ofwaking episodes per cycle of sleep, duration of sleep, mi-
nutes of sleep, and sleep efﬁciency (Abnormal is< 90%) were
calculated using actigraphy data. Room entry checklists were
utilized to record the frequency of nocturnal room entries in
a separate cohort of patients on randomly-selected nights on
the BMT unit.
Results:We obtained 71 nights of sleep for eight patients. Six
patients (75%) were male with a median age of 12.4 years
(IQR 10.6-14.1) at time of actigraphy. Thirty-six nights (51%)
were pretransplant, 35 nights (49%) were post-transplant.
The average sleep onset time was midnight with an average
rise time of 9:00 am. The median duration from onset to
offset was 9.1 hours (IQR 8.0-10.2) with a median duration of
7.1 hours (IQR 6.1-7.8). The median number of waking epi-
sodes per sleep cycle was 12 (IQR 9-17). Median sleep efﬁ-
cacy was 80.7% (IQR 70 to 89%); sleep efﬁciency was
abnormally low 75% of the nights. During 189 nights of room
monitoring, patient’s rooms were entered a median of 12
times per night (IQR 10-15).
Conclusions: These preliminary data suggest that pediatric
patients undergoing SCT often have poor sleep quality while
hospitalized. Frequent room entries, amongst other causes,
may contribute to sleep disruption. Further research is
needed to fully understand the impact of sleep disruption
after HSCT, and evaluate potential interventions to improve
sleep quality.289
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Background: In 2013, the Centers for Disease Control and
Prevention developed a modiﬁcation of blood stream infec-
tion (BSI) deﬁnition, termed mucosal barrier injury labora-
tory-conﬁrmed bloodstream infection (MBI-LCBI). In January
of 2013, the National Healthcare Safety Network (NHSN)
integrated a MBI-LCBI deﬁnition into the methods for BSI
surveillance to aid in identiﬁcation of BSIs reported as central
line associated blood stream infections (CLABSI) likely
related to mucosal barrier injury. There is little literature
describing the timing, patients at risk, and incidence of MBI-
LCBIs in comparison to CLABSIs and BSIs from a secondary
source (secondary BSIs).
Table
Demographics and outcomes of patients a BSI after SCT. 13 patients had >1 infection accounting for 39 total infections.
MBI-LCBI (n¼18) CLABSI
(n¼20)
Secondary BSI
(n¼13)
> 1 BSI after HSCT
(n¼13 patients)
Mean age (years) at SCT (Range) 7.1 (0.9-28.7) 4.6 (0.3-29.8) 5.4 (0.9-32.8) 9.2 (2.2-27.5)
Median days from SCT to BSI (IQR) 7 (4-55) 59 (8-137) 70 (48-118) 149 (58-313)
Diagnosis
Immune Deﬁciency (n¼32)
Malignancy (n¼17)
Marrow Failure (n¼8)
Benign Hematology (n¼5)
Genetic/Metabolic (n¼2)
8 (44%) 13 (65%) 4 (31%) 7 (54%)
6 (33%) 5 (25%) 3 (23%) 3 (23%)
2 (11%) 0 3 (23%) 3 (23%)
1 (6%) 1 (5%) 3 (23%) 0
1(6%) 1 (5%) 0 0
Myeloablative conditioning (n¼28) 8 (44%) 12 (60%) 5 (38%) 3 (23%)
GVHD (Grade II-IV) at 100 days (n¼19) 4 (22%) 5 (25%) 6 (46%) 4 (31%)
Sepsis/shock (n¼31) 4 (22%) 10 (50%) 3 (23%) 14 (36%)
ICU care within 7 days of BSI (n¼15) 4 (22%) 4 (20%) 3 (23%) 4 (10%)
Died (n¼27) 8 (44%) 8 (40%) 3 (23%) 8 (62%)
Non relapsed mortality (n¼20) 6 (33%) 6 (30%) 3 (23%) 5 (38%)
Median days from BSI to death (IQR) 90 (51-152) 119 (50-206) 44 (34-63)
In patients with > 1 BSI, median days from
last BSI to death (IQR)
156 (113-302)
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2011 to April 2014 at our center to determine the timing,
underlying diagnosis, and outcomes of patients diagnosed
with MBI-LCBIs, CLABSIs and secondary BSIs after stem cell
transplant (SCT). We applied the newMBI-LCBI classiﬁcation
to patients undergoing SCT prior to NHSN criteria
implementation.
Results: 299 patients underwent SCT during the 36-month
study period. 34 CLABSIs, 30 MBI-LCBIs, and 26 secondary
BSIs were diagnosed in 64 patients (21%). Thirteen patients
(20%) had more than one infection accounting for 39 of the
90 (43%) infections. MBI-LCBIs occurred shortly after SCT at a
median of 7 days after transplant. 11 of 14 patients with MBI-
LCBIs after day +30 (including patients with > 1 infection)
were diagnosed with GVHD, with 10/11 having GI-GVHD.
Conclusions: One third of BSIs were classiﬁed as an MBI-
LCBI. MBI-LCBIs occurred earlier after SCT than CLABSIs and
secondary BSIs, likely due to mucositis, and were associated
with GVHD after day +30. As the MBI-LCBI classiﬁcation is
new, further research is needed to understand the patho-
genesis and prevention of MBI-LCBIs.Table
Patients diagnosed with BO and PH after HSCT
Diagnosis Age
at SCT
(years)
Days from
SCT to
diagnosis
of BO
Days from
SCT to
diagnosis
of PH
Days from
SCT to death
WiskottAldrich 0.6 233 235 Alive
AML 17.4 305 351 352
CML 10.4 158 247 1368
Aplastic Anemia 5.4 131 No diagnosis
of PH
192290
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Background: Bronchiolitis obliterans (BO) and pulmonary
hypertension (PH) are rare and fatal complications of stem
cell transplantation (SCT). BO is a non-reversible obstructive
lung disease in which bronchioles are compressed and nar-
rowed by ﬁbrosis and/or inﬂammation. PH arises fromincreased pulmonary vascular resistance leading to
increased right ventricular pressure, right heart failure, and
death. PH has not been described in patients with BO after
SCT.
Design/Methods: To evaluate PH in patients with BO, we
retrospectively reviewed all cases of BO in 291 patients un-
dergoing allogeneic HSCT from January 2009 to December of
2012. Patients diagnosed with BO met standard criteria for
BO diagnosis including high resolution CT evidence of air-
trapping. PH was diagnosed with echocardiography, cardiac
catheterization, and autopsy.
Results: Four patients (1.4%) were diagnosed with BO. All
four patients had a history of graft versus host disease, no
infectious cause of respiratory symptoms, and high resolu-
tion CT evidence of BO. Two patients received PFT testing
which showed decreased FEV1. All patients received serial
echocardiography after SCT. Three of the four patients were
diagnosed with PH after the diagnosis of BO (Table). All three
patients had elevated estimated right ventricular pressure,
with secondary signs of PH, on echocardiography. One pa-
tient underwent cardiac catheterization conﬁrming PH, and
one had ﬁndings consistent with PH on autopsy (Figure).
Two patients died from respiratory failure, both received
inhaled nitric oxide. The surviving patient with PH and BO
required intermittent non-invasive ventilation and was
treated with sildenaﬁl for PH. The patient without PH died
192 days after SCT.
Conclusion: PH has not been described in patients with BO
after SCT. The etiology of PH after BO is unclear; however,
parenchymal changes in BO may lead to pulmonary vascular
injury and hypertrophy. Also, long-term hypoxemia and
inﬂammation can lead to vasoconstriction, vascular remod-
eling and angiogenesis, which in turn leads to increased
